Maintenance therapy for multiple myeloma with particular emphasis on thalidomide

Onkologie

Volumn 29, Issue 12, 2006, Pages 582-590

  Durk H A ^a  

^a St Marien Hospital Hamm   (Germany)

Author keywords

Interferon; Maintenance therapy; Myeloma; Prednisone; Thalidomide

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COUMARIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; INTERFERON; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHYLPREDNISOLONE; PAMIDRONIC ACID; PREDNISONE; SEDATIVE AGENT; STEROID; THALIDOMIDE;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTIFICIAL HEART PACEMAKER; ATAXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; BRADYCARDIA; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DIZZINESS; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; EMBOLISM; FATIGUE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOTHYROIDISM; IMMUNOMODULATION; INTESTINE OBSTRUCTION; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; RASH; REVIEW; RISK FACTOR; SOMNOLENCE; STROKE; SURVIVAL RATE; SURVIVAL TIME; TERATOGENICITY; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREMOR; VENOUS THROMBOEMBOLISM; VERTIGO; XEROSTOMIA;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DEXAMETHASONE; HUMANS; INTERFERON-ALPHA; MULTIPLE MYELOMA; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PREDNISONE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33845793924     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096262     Document Type: Review

References (64)

1. Durie BG, Kyle RA, Belch A, et al.; Scientific Advisors of the International Myeloma Foundation: Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-98.
2. Barosi G, Boccadoro M, Cavo M, et al.: Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89:717-41.
3. Glasmacher A, Hahn C, Hoffmann F, et al.: A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2005;132:584-93.
4. Franks ME, Macpherson GR, Figg WD: Thalidomide. Lancet 2004;363:1802-11.
5. Cavo M, Zamagni E, Tosi P, et al.; for the writing committee of the Bologna 2002 study: Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.
6. Palumbo A, Bringhen S, Musto P, et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: a randomised controlled trial. Lancet 2006;367:825-31.
7. Berenson JR, Crowley JJ, Grogan TM, et al.: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163-8.
8. Salmon SE, Crowley JJ, Balcerzak SP, et al.: Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998;16:890-6.
9. Shustik C, Belch A, Robinson S, et al.: Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group study: MY7. Proc Amer Soc Clin Oncol 2004;23:abstr 6510.
10. Alexanian R, Weber D, Dimopoulos M, et al.: Randomized trial of a-interferon or dexamethason as maintenance treatment for multiple myeloma. Am J Hematol 2000;65:204-9.
11. Chen CI, Nanji S, Prabhu A, et al.: Sequential, cycling maintenance therapy for post transplant multiple myeloma. Bone Marrow Transplant 2006;37:89-94.
12. Barlogie B, Kyle RA, Anderson KC, et al.: Standard chemotherapy compared with high-dose chemoradiotherapy: final results of phase III US Intergroup Trial S9321 for Multiple Myeloma. J Clin Oncol 2006;24:929-36.
13. Cunningham D, Powles R, Malpas J, et al.: A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998;102:495-502.
14. Ludwig H, Fritz E: Interferon in multiple myeloma - summary of treatment results and clinical implications. Acta Oncol 2000;39:815-21.
15. The Myeloma Trialists' Collaborative Group: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Hematol 2001;113:1020-34.
16. Salmon SE, Crowley JJ, Grogan TM, et al.: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2405-14.
17. Peest D, Deicher H, Coldewey R, et al.: A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferonalpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995;31:146-51.
18. Drayson MT, Chapman CE, Dunn JA, et al.: MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998;101:195-202.
19. Wada M, Mizoguchi H, Kuriya SI, et al.: Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan. Br J Haematol 2000;109:805-14.
20. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, et al.: Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005;16:634-9.
21. Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000;26:351-62.
22. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16.
23. Hideshima T, Chauhan D, Shima Y, et al.: Thalidomide (Thal) and its analogues overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. Blood 2000;96:2943-50.
24. Anderson KC: Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Semin Hematol 2005;42:S3-S8.
25. Kyriakou C, Thomson K, D'Sa S, et al.: Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005;129:763-70.
26. Barlogie B, Desikan R, Eddlemon P, et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
27. Stewart AK, Chen CI, Howson-Jan K, et al.: Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantat. Clin Cancer Res 2004;10:8170-76.
28. Ludwig H, Drach J, Tothova E, et al.: Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis. Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Hannover 2.-5.10.2005, Vortrag 038.
29. Rajkumar SV, Blood E, Vesole DH, et al.: Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood 2004;104:A205.
30. Tosi P, Zamagni E, Cellini C, et al.: Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212-6.
31. Dimopoulos MA, Hamilos G, Zomas A, et al.: Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004;5:112-7.
32. Neben K, Moehler T, Benner A, et al.: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002;8:3377-82.
33. Palumbo A, Bertola A, Falco P, et al.: Efficacy of low-thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004;5:318-24.
34. Mileshkin L, Biagi JJ, Mitchell P, et al.: Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69-77.
35. Richardson P, Jagannath S, Schlossman R, et al.: Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. Blood 2002;100:813a(abstr 3212).
36. Schey SA, Cavenagh J, Johnson R, et al.: An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Res 2003;27:909-14.
37. Kumar S, Gertz MA, Dispenzieri A, et al.: Response rate, durability of response and survival after thalidomide therapie for relapsed multiple myeloma. Mayo Clin Proc 2003;78:34-9.
38. Hus M, Dmoszynska A, Soroka-Wojtazko M, et al.; for the Polish Multiple Myeloma Study Group: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001;86:404-8.
39. Steurer M, Spizzo G, Mitterer M, et al.: Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie 2004;27:150-4.
40. Johnston RE, Abdalla SH: Thalidomide in low dose is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002;43:351-4.
41. Daneschvar HL, Daw H, Chaudhry A, et al.: Thalidomide in multiple myeloma - a community hospital experience. Blood 2005;106:abstr 5140.
42. Bladé J, Esteve J, Rosinol L, et al.: Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001;28:588-92.
43. Zangari M, Barlogie B, Anaissie E, et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-21.
44. Goldschmidt H, Sonneveld P, Breitkreuz I, et al.; HOVON 50/GMMG-HD3-Trial: Phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. Blood 2005;106:abstr 424.
45. Ikhlaque N: Efficacy of prophylactic anticoagulation to prevent thalidomide-related deep venous thrombosis. Blood 2005;106:abstr 5132.
46. Alexanian R, Weber D, Giralt S, et al.: Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002;13:1116-9.
47. Attal M, Harousseau JL, Leyvraz S, et al.; for the Inter-Groupe Francophone du Myéloma (IFM): Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006 (Epub ahead of print), DOI 10,1182/blood-2006-05-022962.
48. Feyler S, Rawstron A, Jackson G, et al.: Thalidomide maintenance following high dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Blood 2005;106:abstr 641.
49. Barlogie B, Tricot G, Anaissie E, et al.: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.
50. Sahebi F, Spielberger R, Kogut NM, et al.: Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006;37:825-9.
51. Krivanova A, Hajek R, Krejci M, et al.; Czech Myeloma Group: Second autologous transplantation for multiple myeloma patients relapsing after the first autograft - a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie 2004;27:275-9.
52. Kovacs MJ, Chapman JAW, Shepherd L, et al.; The NCIC CTG Investigators on MY.10: Maintenance therapy with thalidomide/prednisone post autologous stem cell transplant for patients with multiple myeloma elevates D-dimer and possibly factor VIII levels. Blood 2005;106:abstr 2561.
53. Yakoub-Agha I, Hulin C, Doyen C, et al.: A multicenter prospective randomized study testing noninferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: first results of the final analysis of the IFM 01-02 study. Blood 2005;106:abstr 364.
54. Cavaletti G, Beronio A, Reni L, et al.: Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004;62:2291-3.
55. Fahdi IE, Gaddam V, Saucedo JF, et al.: Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 2004;93:1052-5.
56. Beall G, Sanwo M, Hussain H: Allergic disease in AIDS. Drug reactions and desensitization in AIDS. Immunol Allergy Clin North Am 1997;17:319-38.
57. Nijsten T, Meuleman L, Schroyens W, et al.: Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone. Dermatology 2002;204:365-7.
58. Castro J, Davila J, Perez S, et al.: High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide(T) as maintenance in patients (P) with multiple myeloma (MM). Blood 2003;102:abstr 5691.
59. Santos ES, Goodman M, Byrnes JJ, et al.: Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology 2004;9:35-9.
60. Gil L, Drozdowska D, Czyz A, et al.: Thalidomide as maintenance therapy after autologous stem cell transplantation in patients with multiple myeloma. Hematol J 2003;4(suppl 2):abstr 0249.
61. Fenk R, Graef T, Bruns I, et al.: Comparison of interferon versus thalidomide versus RIC allotransplant for maintenance / consolidation therapy after autologous stem cell transplantation in patients with multiple myeloma. Blood 2005;106:abstr 1168.
62. Lonial S, Brinker B, Waller EK, Langston AA, Redei I, Smith K, Bucur S, Winton E, Lyles R, Heffner LT: Maintenance or salvage therapy with thalidomide enhances overall survival following autologous hematopoietic progenitor cell transplantation for multiple myeloma. Hematol J 2003;4(suppl 1):A346.
63. Masszi T, Reményi P, Bátai, et al.: Thalidomide maintenance following autologous stem cell transplantation prolongs progression-free and overall survival in multiple myeloma - retrospective analysis of 111 patients at a single centre. 10th Congress of the European Hematology Association, Stockholm 2005, A0631.
64. Mettivier V, Pezzullo L, Finizio O, et al.: Maintenance with low dose thalidomide in multiple myeloma patients after auto transplantation. 10th Congress of the European Hematology Association, Stockholm 2005, A0948.